{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:02:46Z","timestamp":1720220566550},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.thromres.2016.12.001","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T02:45:50Z","timestamp":1481078750000},"page":"87-92","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism"],"prefix":"10.1016","volume":"152","author":[{"given":"Franco","family":"Piovella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana I.","family":"Iosub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2016.12.001_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.beha.2012.06.007","article-title":"Venous thromboembolism: epidemiology and magnitude of the problem","volume":"25","author":"Goldhaber","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0020","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2016.12.001_bb0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0030","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0035","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0045","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0060","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1538-7836.2012.04662.x","article-title":"Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH","volume":"10","author":"Baglin","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.12.001_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2016.12.001_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2016.12.001_bb0080","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002001","article-title":"Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism","author":"van der Heijden","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.thromres.2016.12.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006652.pub4","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","volume":"7","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.thromres.2016.12.001_bb0095","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"van Gogh Investigators","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2016.12.001_bb0105","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2016.12.001_bb0110","series-title":"Clinical Guidelines, CG144","article-title":"Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"10.1016\/j.thromres.2016.12.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12239","article-title":"The predictive ability of bleeding risk stratification models in very old patients on VKA treatment for venous thromboembolism Results of the Prospective Collaborative EPICA study","author":"Poli","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.12.001_bb0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11739-012-0844-3","article-title":"Patient preferences and willingness to pay for different options of anticoagulant therapy","volume":"8","author":"Moia","year":"2013","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","article-title":"Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer","volume":"17","author":"Fallowfield","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543784.16.4.431","article-title":"Investigational treatments of venous thromboembolism","volume":"16","author":"Spyropoulos","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.thromres.2016.12.001_bb0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1160\/TH15-08-0670","article-title":"European Union-28: an annualised cost-of-illness model for venous thromboembolism","volume":"115","author":"Barco","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.12.001_bb0145","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1185\/03007995.2013.879439","article-title":"Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism","volume":"30","author":"van Bellen","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.thromres.2016.12.001_bb0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2014.946993","article-title":"Length of stay and economic consequences with rivaroxaban vs enoxaparin\/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program","volume":"17","author":"Bookhart","year":"2014","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.thromres.2016.12.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002340","article-title":"Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-vein Thrombosis as First-line Therapy (AMPLIFY) trial","volume":"4","author":"Liu","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2016.12.001_bb0160","first-page":"301","article-title":"Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis","volume":"33","author":"Alotaibi","year":"2014","journal-title":"Int. Angiol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0165","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","article-title":"Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"134","author":"G\u00f3mez-Outes","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2016.12.001_bb0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.thromres.2016.05.022","article-title":"Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism","volume":"144","author":"Bauersachs","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2016.12.001_bb0175","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2141.2008.07141.x","article-title":"Venous thromboembolism in hospitalised patients: a public health crisis?","volume":"141","author":"Baglin","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.5858\/arpa.2012-0296-CP","article-title":"D-dimer: simple test, tough problems","volume":"137","author":"Olson","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCP.0b013e328363ed7c","article-title":"Assessing recurrence risk following acute venous thromboembolism: use of algorithms","volume":"19","author":"Poli","year":"2013","journal-title":"Curr. Opin Pulm. Med."},{"key":"10.1016\/j.thromres.2016.12.001_bb0190","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2016.12.001_bb0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09540120050042891","article-title":"Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG)","volume":"12","author":"Chesney","year":"2000","journal-title":"AIDS Care"},{"key":"10.1016\/j.thromres.2016.12.001_bb0200","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag. Healthc. Policy"},{"key":"10.1016\/j.thromres.2016.12.001_bb0205","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.12.001_bb0210","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0215","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2016.12.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","author":"Lauffenburger","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2016.12.001_bb0225","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1160\/TH15-02-0131","article-title":"Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study","volume":"114","author":"Weitz","year":"2015","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816306454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816306454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T13:23:18Z","timestamp":1531660998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816306454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":45,"alternative-id":["S0049384816306454"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.12.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}